Tag:
multiple sclerosis
Latest Headlines
Latest Headlines
XenoPort shares skid after MS drug proves to be a lemon in PhIII
Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by multiple sclerosis. The troubled biopharma company, which has been struggling to spur sales for the approved drug Horizant for restless leg syndrome, immediately opted to bury the program.
Biotech Receptos claims $73M IPO prize to fuel oral MS contender
San Diego-based biotech Receptos has priced an initial public offering of 5.2 million shares at $14, raising $72.8 million as the company closes in on late-stage development of its lead candidate for multiple sclerosis.
Brain atrophy could predict MS, study finds
Using MRI scans to measure tissue atrophy in the thalamus can accurately predict multiple sclerosis, according to new research, pointing the way to a more reliable biomarker than current methods.
Biogen MS pill soars onstage with impressive first-week script numbers
Biogen Idec's new multiple sclerosis pill made its debut to high expectations earlier this month. And so far, Tecfidera hasn't disappointed. As The Street reports, the drug has literally leapt onto the market. Its first week's worth of prescriptions surpassed 300, a rate that Novartis' first-to-market rival didn't hit until almost three months after launch.
Scientists develop technique to rebuild brain cells destroyed by MS, cerebral palsy
Scientists at Cleveland's Case Western Reserve School of Medicine have developed a technique in mice that converts skin cells to the kind of brain cells that get damaged in diseases like multiple sclerosis, cerebral palsy and other so-called myelin disorders.
Biogen Idec shares surge on positive multiple sclerosis drug data
Shares of Biogen Idec ($BIIB) surged to around the $197 mark this morning as the company detailed data on its promising Phase IIb study of the multiple sclerosis drug daclizumab.
Novartis aims new Gilenya campaign at young MS patients
Novartis is thinking young. The Swiss drugmaker is using a cheeky ad campaign, targeted at 20- and 30-somethings not only in magazines, but via websites and social media. Novartis needs to find a new edge in the MS market, where it faces not only well-established injectable drugs, but two new oral rivals.
Biogen Idec's new oral MS drug offers novel approach
Biogen Idec's recently approved Tecfidera, a blockbuster oral treatment for multiple sclerosis, is set to hit pharmacies this week, filling the need for a safe and effective option for patients with the disease.
Biogen prices Tecfidera below oral MS rival Gilenya
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
Biogen's Tecfidera expected to hit the MS market running
The FDA gave its final blessing to Biogen Idec's much-anticipated multiple sclerosis pill Tecfidera. It's the third oral MS treatment to hit a market long limited to injectable drugs. But Biogen believes--and many analysts agree--that Tecfidera can surpass its oral competitors, and quickly.
